Home > Insider Trading > Filing (0000911916-16-000652)

Filing Details

Accession Number:: 0000911916-16-000652
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-09-07 17:56:46
Reporting Period:: 2016-09-05

Filing Date:: 2016-09-07
Accepted Time:: 2016-09-07 17:56:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348649	Colucid Pharmaceuticals Inc.	CLCD	Pharmaceutical Preparations (2834)	203419541

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1639978	P. Thomas Mathers	C/O Colucid Pharmaceuticals, Inc. 222 Third Street Cambridge MA 02142	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-09-05	3,756	$0.00	256,916	No	4	M	Direct
Common Stock	Disposition	2016-09-06	1,502	$19.50	255,414	No	4	S	Direct
Common Stock	Disposition	2016-09-07	663	$20.56	254,751	No	4	S	Direct
Common Stock	Disposition	2016-09-07	962	$21.90	253,789	No	4	S	Direct
Common Stock	Disposition	2016-09-07	2,633	$22.62	251,156	No	4	S	Direct
Common Stock	Disposition	2016-09-07	442	$23.43	250,714	No	4	S	Direct
Common Stock	Disposition	2016-09-07	300	$24.40	250,414	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2016-09-05	3,756	$0.00	3,756	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
120,168			No	4	M	Direct

Footnotes

Each restricted stock unit ("RSU") represents a contingent right to receive one share of CoLucid Pharmaceuticals, Inc. common stock.
Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Mathers on August 19, 2016. The purpose of the plan was to sell shares of common stock in order to pay the taxes related to the settlement of the RSUs.
Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Mathers on August 19, 2016. The purpose of the plan is to sell shares of common stock acquired under the CoLucidPharmaceuticals, Inc. Employee Stock Purchase Plan.
Represents the sale of 663 shares in multiple transactions, ranging in price from $20.13 to $21.07 per share, resulting in a weighted average sale price of $20.5555. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
Represents the sale of 962 shares in multiple transactions, ranging in price from $21.18 to $22.16 per share, resulting in a weighted average sale price of $21.9045. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
Represents the sale of 2,633 shares in multiple transactions, ranging in price from $22.18 to $23.12 per share, resulting in a weighted average sale price of $22.6164. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
Represents the sale of 442 shares in multiple transactions, ranging in price from $23.20 to $24.00 per share, resulting in a weighted average sale price of $23.4267. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
Represents the sale of 300 shares in multiple transactions, ranging in price from $24.26 to $24.48 per share, resulting in a weighted average sale price of $24.3967. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
On May 5, 2015, the reporting person received 360,508 RSUs. Those RSUs vest as follows: 50% of the RSUs vested on November 5, 2015; 12.5% of the RSUs vested on May 5, 2016; and the remaining RSUs vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.